uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Earnings for uniQure N.V. (QURE)
Earnings in 2023 (TTM): $-306,557,000
According to uniQure N.V.'s latest financial reports the company's current earnings (TTM) are $-306,557,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of uniQure N.V.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-306,557,000 | $-308,478,000 |
| 2022 | $-128,259,000 | $-126,789,000 |
| 2021 | $332.81 M | $329.59 M |
| 2020 | $-141,443,000 | $-125,024,000 |
| 2019 | $-124,201,000 | $-128,011,000 |
| 2018 | $-83,073,000 | $-83,304,000 |
| 2017 | $-80,588,000 | $-80,389,000 |
| 2016 | $-72,229,000 | $-73,374,000 |
| 2015 | $-78,620,471 | $-78,149,258 |
| 2014 | $-45,041,101 | $-45,041,101 |
| 2013 | $-37,034,991 | $-37,034,991 |
| 2012 | $-19,462,004 | $-19,462,004 |
| 2011 | $-22,422,396 | $-22,422,396 |